GlassScriptPhysician profile
Christina E Baker
NPI 1619402070
$3,408.92
in general payments reported to CMS, 2019-2025
34 companies · $424 in 2025
The $424 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $760 · 2023: $789 · 2024: $1,435 · 2025: $424.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,635 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,635.29 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $697.63 | 2022-2025 | |
| Novo Nordisk INC | $258.87 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $254.70 | 2022-2025 | |
| Daiichi Sankyo INC. | $223.71 | 2023-2025 | Injectafer |
| Janssen Pharmaceuticals, INC | $219.03 | 2022-2025 | Spravato, Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $162.53 | 2022-2024 | |
| Lilly USA, LLC | $134.34 | 2022-2025 | Jardiance, Zepbound, Mounjaro |
| Glaxosmithkline, LLC. | $128.79 | 2022-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.24 | 2022-2024 | Spiriva Respimat, Jardiance, Ofev |
| Novartis Pharmaceuticals Corporation | $108.89 | 2023-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $100.31 | 2022 | |
| Astellas Pharma US INC | $81.80 | 2023-2025 | Veozah |
| Amgen INC. | $74.26 | 2024-2025 | Evenity, Prolia |
| Aimmune Therapeutics, INC. | $73.62 | 2024-2025 | Zenpep |
| Exact Sciences Corporation | $71.19 | 2023-2024 | Cologuard Collection Kit |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $69.29 | 2023-2024 | Gemtesa |
| Azurity Pharmaceuticals, INC. | $66.05 | 2024 | Edarbyclor |
| Dexcom, INC. | $65.89 | 2024-2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $63.20 | 2023-2025 | Breztri, Airsupra |
| Lundbeck LLC | $57.07 | 2024 | Rexulti |
| Xeris Pharmaceuticals, INC. | $52.40 | 2024 | Gvoke Hypopen |
| Merck Sharp & Dohme LLC | $47.76 | 2022-2024 | Verquvo, Gardasil 9, Gardasil |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.49 | 2022-2025 | Xifaxan |
| Nestle Healthcare Nutrition INC. | $35.43 | 2023 | |
| Vivus LLC | $31.43 | 2024-2025 | Qsymia |
| Teva Pharmaceuticals USA, INC. | $31.06 | 2024-2025 | Ajovy |
| Neurocrine Biosciences, INC. | $26.21 | 2023-2024 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $16.61 | 2023 | Camzyos |
| Ardelyx, INC. | $16.29 | 2024 | Ibsrela |
| Inspire Medical Systems, INC. | $16.29 | 2024 | Inspire |
| Otsuka America Pharmaceutical, INC. | $15.88 | 2024 | Rexulti |
| Optinose US, INC. | $15.87 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.81 | 2023 | Trintellix |
| Idorsia Pharmaceuticals US INC | $13.98 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christina Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.